Across TCGA pan-cancer cohorts, ACSM5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ACSM5 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACSM5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACSM5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where ACSM5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.255	0.685	.010	24	view →
CCRCC	OS	Quartile	III,IV	0.834	0.504	.031	10	view →
GBM	DFS	Median	All	0.444	0.277	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ACSM5 tumor-vs-normal RNA expression · all ACSM5 data types